Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717311 | 1.00 | GPR3 (0.48) | GPR3LIMK1CDK5CDK5R1GABRA1 | |
| SCHEMBL22250075 | 0.82 | EGFR (0.32) | GABRA1GABRPGABRDGABRB1GABRG2 | |
| SCHEMBL24270404 | 0.81 | CYP2A6 (0.34) | EGFR | |
| SCHEMBL24270400 | 0.79 | KDM4E (0.36) | LIMK1CDK5ALDH1A1HPGDEGFR | |
| SCHEMBL26423557 | 0.79 | EGFR (0.39) | ALDH1A1HPGDRAB9ASMN1; SMN2EGFR | |
| SCHEMBL19579029 | 0.79 | LIMK1 (0.37) | GPR3LIMK1CDK5CDK5R1ALDH1A1 | |
| SCHEMBL25463878 | 0.78 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24270403 | 0.77 | LIMK1 (0.44) | LIMK1ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL24270401 | 0.77 | LIMK1 (0.41) | LIMK1ALDH1A1MAPTSMN1; SMN2ALOX15 | |
| SCHEMBL16919859 | 0.75 | BCL2L1 (0.36) | MAPTHPGDRAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009104027-A1 | THERAPEUTIC APPLICATION OF TRICICLIC AROMATIC AND SATURATED BENZO(4,5)THIENO-(2,3-D)PYRIMIDINE DERIVATES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| US-20250194404-A1 | ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANOMETALLIC COMPOUND AND VARIOUS TYPES OF HOST MATERIALS | LG DISPLAY CO., LTD. (KR) | 2025-06-12 | — | — | US | disclosed |
| US-20240246923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | LT MATERIALS CO., LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-12048237-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240074306-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | LT MATERIALS CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-11891361-B2 | Heterocyclic compound and organic light emitting device comprising same | LT MATERIALS CO., LTD. (KR) | 2024-02-06 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230389413-A1 | Organic Electroluminescent Materials and Devices | UNIVERSAL DISPLAY CORPORATION | 2023-11-30 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1635840-A1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Solvay Pharmaceuticals B.V. (NL) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| WO-2004110459-A1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-12-23 | — | — | WO | disclosed |
| US-4234581-A | ANTIALLERGENS | MEAD JOHNSON & COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-4159377-A | ANTIALLERGENS | MEAD JOHNSON & COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4054656-A | ASTHMA, HAY FEVER, FOODS | MEAD JOHNSON & COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230389413-A1 | Organic Electroluminescent Materials and Devices | GLRA3, ESRRG, GLRA1 | GPR3 46/4885LIMK1 2662/4885CDK5 4422/4885 |
| US-11891361-B2 | Heterocyclic compound and organic light emitting device comprising same | CRY1, CYP1A1, CYP1B1 | GPR3 2570/4885LIMK1 537/4885CDK5 1305/4885 |
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | HSD17B1, HSD17B3, HSD17B2 | GPR3 2753/4885LIMK1 4060/4885CDK5 1164/4885 |
| US-20240246923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | CYP1A1, CYP1B1, CRY1 | GPR3 2807/4885LIMK1 421/4885CDK5 1394/4885 |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | NR4A1, CYP1A1, ARNT | GPR3 858/4885LIMK1 840/4885CDK5 2736/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | GPR3 334/4885LIMK1 4241/4885CDK5 241/4885 |
| US-12048237-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OSBP | GPR3 2810/4885LIMK1 1588/4885CDK5 3645/4885 |
| US-20240074306-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | CYP1B1, NOTUM, WEE1 | GPR3 3884/4885LIMK1 326/4885CDK5 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.